Abstract
Neuroinflammatory processes appear to play a fundamental role in the pathology associated with a number of neurodegenerative and psychiatric conditions. In this respect, the immunocompetent brain microglia and peripheral macrophages release a host of proinflammatory cytokines that not only modulate immunological processes but also influence neuronal functioning and even survival. For instance, alterations of the cytokines, tumor necrosis factor-α, as well as several of the interferons and interleukins have been associated with Parkinson;s disease (PD) and clinical depression. Importantly, anti-inflammatory treatments that block these cytokines may impart protection against behavioural pathology and neuronal damage in animal models of PD and depression involving exposure to environmental toxins and stressors, respectively. The present review highlights the involvement of inflammatory cells and cytokines in depression and PD and explores some of the potential cellular and molecular mechanisms through which the immunotransmitters affect neuronal functioning. Attention is also devoted to the possibility that cytokines may sensitize neuroinflammatory pathways that, in turn, favour long-term pathology.
Keywords: cytokine, sensitization, depression, parkinsons disease, neurodegeneration, microglia, neurochemical, neurotoxin
Current Pharmaceutical Design
Title: Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Volume: 11 Issue: 8
Author(s): Shawn Hayley and Hymie Anisman
Affiliation:
Keywords: cytokine, sensitization, depression, parkinsons disease, neurodegeneration, microglia, neurochemical, neurotoxin
Abstract: Neuroinflammatory processes appear to play a fundamental role in the pathology associated with a number of neurodegenerative and psychiatric conditions. In this respect, the immunocompetent brain microglia and peripheral macrophages release a host of proinflammatory cytokines that not only modulate immunological processes but also influence neuronal functioning and even survival. For instance, alterations of the cytokines, tumor necrosis factor-α, as well as several of the interferons and interleukins have been associated with Parkinson;s disease (PD) and clinical depression. Importantly, anti-inflammatory treatments that block these cytokines may impart protection against behavioural pathology and neuronal damage in animal models of PD and depression involving exposure to environmental toxins and stressors, respectively. The present review highlights the involvement of inflammatory cells and cytokines in depression and PD and explores some of the potential cellular and molecular mechanisms through which the immunotransmitters affect neuronal functioning. Attention is also devoted to the possibility that cytokines may sensitize neuroinflammatory pathways that, in turn, favour long-term pathology.
Export Options
About this article
Cite this article as:
Hayley Shawn and Anisman Hymie, Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates, Current Pharmaceutical Design 2005; 11 (8) . https://dx.doi.org/10.2174/1381612053381611
DOI https://dx.doi.org/10.2174/1381612053381611 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Resistance is Associated with Subclinical Vascular Injury in Patients with a Kidney Disease
Current Cardiology Reviews Management of Statin-Intolerant High-Risk Patients
Current Vascular Pharmacology Genesis of Dihydropyrimidinone Calcium Channel Blockers: Recent Progress in Structure-Activity Relationships and Other Effects
Mini-Reviews in Medicinal Chemistry Towards More Efficient Glutathione Peroxidase Mimics: Substrate Recognition and Catalytic Group Assembly
Current Medicinal Chemistry Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism New Treatments for COPD in the Elderly
Current Pharmaceutical Design Group A Streptococcal Vaccine Candidates based on the Conserved Conformational Epitope from M Protein
Drug Delivery Letters Value of Coronary Calcium Scoring in Symptomatic and Asymptomatic Coronary Artery Disease Patients
Current Medical Imaging Predicting Drug Metabolism Induction In Silico
Current Topics in Medicinal Chemistry Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Green Synthesis of Novel Phthalimide Derivatives of Aspirin and P-aminosalicylic Acid as Potential Analgesic- antipyretic and Anti-tuberculosis Agents
Letters in Organic Chemistry Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Complementary and Alternative Medicine for the Treatment of Insomnia: An Overview of Scientific Evidence from 2008 to 2018
Current Vascular Pharmacology Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued) Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy
Current Drug Delivery Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Long-Acting Antipsychotic Medications
Current Drug Targets